MAPK3 and neoplasm: In cancer, aberrant activation of the ERK1/2 pathway often results in enhanced cell proliferation and resistance to apoptosis (Zhang et al., 2020[149]; Zhou et al., 2011[152]), contributing to tumor growth and metastasis.